Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants

被引:7
作者
Chaki, Sankar Prasad [1 ]
Kahl-McDonagh, Melissa M. [1 ]
Neuman, Benjamin W. [1 ,2 ]
Zuelke, Kurt A. [1 ]
机构
[1] Texas A&M Univ, Texas A&M Global Hlth Res Complex, Div Res, College Stn, TX 77843 USA
[2] Texas A&M Univ, Coll Sci, Dept Biol, College Stn, TX 77843 USA
关键词
SARS-CoV-2; receptor-binding motif (RBM); Sanger sequencing; mutations; variant surveillance; Alpha variant; Delta variant; Omicron variant; lineages;
D O I
10.1128/spectrum.00665-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic resulted in 427 million infections and 5.9 million deaths globally as of 21 February 2022. SARS-CoV-2, the causative agent of the COVID-19 pandemic, frequently mutates and has developed into variants of major public health concerns. Whole-genome sequencing (WGS) is the gold standard for characterizing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and identification of new variants. However, the cost involved and time needed for WGS prevent routine, rapid clinical use. This study aimed to develop a quick and cost-effective surveillance strategy for SARS-CoV-2 variants in saliva and nasal swab samples by spike protein receptor-binding-motif (RBM)-targeted Sanger sequencing. Saliva and nasal swabs prescreened for the presence of the nucleocapsid (N) gene of SARS-CoV-2 were subjected to RBM-specific single-amplicon generation and Sanger sequencing. Sequences were aligned by CLC Sequence Viewer 8, and variants were identified based upon specific mutation signature. Based on this strategy, the present study identified Alpha, Beta/Gamma, Delta, and Omicron variants in a quick and cost-effective manner. IMPORTANCE The coronavirus disease 2019 (COVID-19) pandemic resulted in 427 million infections and 5.9 million deaths globally as of 21 February 2022. SARS-CoV-2, the causative agent of the COVID-19 pandemic, frequently mutates and has developed into variants of major public health concerns. Following the Alpha variant (B.1.1.7) infection wave, the Delta variant (B.1.617.2) became prevalent, and now the recently identified Omicron (B.1.1.529) variant is spreading rapidly and forming BA.1, BA.1.1, BA.2, BA.3, BA.4, and BA.5 lineages of concern. Prompt identification of mutational changes in SARS-CoV-2 variants is challenging but critical to managing the disease spread and vaccine/therapeutic modifications. Considering the cost involved and resource limitation of WGS globally, an RBM-targeted Sanger sequencing strategy is adopted in this study for quick molecular surveillance of SARS-CoV-2 variants.
引用
收藏
页数:10
相关论文
共 39 条
[1]   Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion [J].
Benton, Donald J. ;
Wrobel, Antoni G. ;
Xu, Pengqi ;
Roustan, Chloe ;
Martin, Stephen R. ;
Rosenthal, Peter B. ;
Skehel, John J. ;
Gamblin, Steven J. .
NATURE, 2020, 588 (7837) :327-330
[2]   A Sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern [J].
Bezerra, Matheus Filgueira ;
Machado, Lais Ceschini ;
Vasconcelos De Carvalho, Viviane do Carmo ;
Docena, Cassia ;
Brandao-Filho, Sinval Pinto ;
Junqueira Ayres, Constancia Flavia ;
Santos Paiva, Marcelo Henrique ;
Wallau, Gabriel Luz .
INFECTION GENETICS AND EVOLUTION, 2021, 92
[3]  
Cameroni E., 2021, bioRxiv
[4]  
CDC, 2022, SARS COV 2 VAR CLASS
[5]   The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose [J].
Chagla, Zain .
ANNALS OF INTERNAL MEDICINE, 2021, 174 (02) :JC15-JC15
[6]   MINERVA: A Facile Strategy for SARS-CoV-2 Whole-Genome Deep Sequencing of Clinical Samples [J].
Chen, Chen ;
Li, Jizhou ;
Di, Lin ;
Jing, Qiuyu ;
Du, Pengcheng ;
Song, Chuan ;
Li, Jiarui ;
Li, Qiong ;
Cao, Yunlong ;
Xie, X. Sunney ;
Wu, Angela R. ;
Zeng, Hui ;
Huang, Yanyi ;
Wang, Jianbin .
MOLECULAR CELL, 2020, 80 (06) :1123-+
[7]  
Chen J., 2021, ARXIV ARXIV211201318
[8]   Next generation sequencing of SARS-CoV-2 genomes: challenges, applications and opportunities [J].
Chiara, Matteo ;
D'Erchia, Anna Maria ;
Gissi, Carmela ;
Manzari, Caterina ;
Parisi, Antonio ;
Resta, Nicoletta ;
Zambelli, Federico ;
Picardi, Ernesto ;
Pavesi, Giulio ;
Horner, David S. ;
Pesole, Graziano .
BRIEFINGS IN BIOINFORMATICS, 2021, 22 (02) :616-630
[9]   SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses [J].
Dejnirattisai, Wanwisa ;
Huo, Jiandong ;
Zhou, Daming ;
Zahradnik, Jiri ;
Supasa, Piyada ;
Liu, Chang ;
Duyvesteyn, Helen M. E. ;
Ginn, Helen M. ;
Mentzer, Alexander J. ;
Tuekprakhon, Aekkachai ;
Nutalai, Rungtiwa ;
Wang, Beibei ;
Dijokaite, Aiste ;
Khan, Suman ;
Avinoam, Ori ;
Bahar, Mohammad ;
Skelly, Donal ;
Adele, Sandra ;
Johnson, Sile Ann ;
Amini, Ali ;
Ritter, Thomas G. ;
Mason, Chris ;
Dold, Christina ;
Pan, Daniel ;
Assadi, Sara ;
Bellass, Adam ;
Omo-Dare, Nicola ;
Koeckerling, David ;
Flaxman, Amy ;
Jenkin, Daniel ;
Aley, Parvinder K. ;
Voysey, Merryn ;
Clemens, Sue Ann Costa ;
Naveca, Felipe Gomes ;
Nascimento, Valdinete ;
Nascimento, Fernanda ;
da Costa, Cristiano Fernandes ;
Resende, Paola Cristina ;
Pauvolid-Correa, Alex ;
Siqueira, Marilda M. ;
Baillie, Vicky ;
Serafin, Natali ;
Kwatra, Gaurav ;
Da Silva, Kelly ;
Madhi, Shabir A. ;
Nunes, Marta C. ;
Malik, Tariq ;
Openshaw, Peter J. M. ;
Baillie, J. Kenneth ;
Semple, Malcolm G. .
CELL, 2022, 185 (03) :467-+
[10]  
EpiCoV Data Curation Team, 2021, US